CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
瓦解 CAR-T 治疗中的髓系耐药
英文原题：Disarming myeloid resistance in CAR T therapy.
查看英文原题
Disarming myeloid resistance in CAR T therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
揭示 B 细胞淋巴瘤对嵌合抗原受体（CAR）T 细胞治疗产生耐药的机制至关重要。在本期 Cancer Cell 中，Stahl 等人鉴定出一个 CSF1R+ 髓单核细胞群体，该群体破坏 CAR-T 细胞功能，并表明抑制 CSF1R 可增强 CD19 靶向 CAR-T 细胞的疗效。
展开英文摘要原文
Uncovering mechanisms of resistance to chimeric antigen receptor (CAR) T cell therapy for B cell lymphoma is of paramount importance. In this issue of Cancer Cell, Stahl et al. identify a CSF1R + myelo-monocytic population that disrupts CAR T cell function and show that inhibition of CSF1R enhances efficacy of CD19-targeted CAR T cells.
论文信息
- 作者
- Warrington JM、Singh N
- 第一作者单位
- Division of Oncology, Section of Cellular Therapy, Washington University School of Medicine, St. Louis, MO, USA; Center for Gene and Cellular Immunotherapy, Washington University School of Medicine, St. Louis, MO, USA.United States
- 通讯作者单位
- Division of Oncology, Section of Cellular Therapy, Washington University School of Medicine, St. Louis, MO, USA; Center for Gene and Cellular Immunotherapy, Washington University School of Medicine, St. Louis, MO, USA. Electronic address: nathan.singh@wustl.edu.United States
- 期刊
- Cancer cell2025 Aug 11
- 原文标识
- PubMed 40578358 · DOI 10.1016/j.ccell.2025.06.003